Biedermann Medtech to shift U.S. strategy, focus on licensing and services

Biedermann Medtech Group said it will overhaul its U.S. business model, moving away from direct product distribution and focusing instead on licensing and integrated services for its spinal and extremity surgery technologies.

The company said its U.S. subsidiary, Biedermann Motech, will phase out direct distribution of its surgical implant systems in the American market. The decision followed what the company called a “comprehensive and detailed review” of market conditions and broader economic pressures.

Under its new strategy, Biedermann will lean on its partnership with Biedermann Technologies, which holds a significant intellectual property portfolio, to commercialize its U.S. patents and product innovations. The model will include licensing its technologies and products, as well as offering value-added services aimed at hospitals and surgeons.

At the same time, the company said it is seeing growing international demand, particularly in Europe, where recent regulatory changes have sparked increased interest in its CE-marked spinal products. Biedermann Motech said it plans to expand its direct business outside the U.S.

Despite the shift, the company said it will continue investing in research and partnerships in areas such as minimally invasive surgery, complex deformity procedures, outpatient fusion surgery and new enabling technologies.

“Our goal is to have a profound and beneficial impact on surgical processes and results, ultimately enhancing patient outcomes inside and outside the U.S.,” the company said in its announcement.